DFDelphine Farlay

Delphine Farlay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Delphine Farlay has a total of 245 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improvement of bone properties in children with osteogenesis imperfecta after pamidronate: a bone biopsy study

    by Delphine Farlay, Mathilde Cornier, Sébastien Rizzo, Valérie Cormier-Daire, Maelle Charpié, Graziella Pinto, Hina Simonnet, Isabelle Badoud, Maude Gerbaix, Pascale Chavassieux, et al.

    OI, or bone brittle disease, is characterized by increased mineralization of bone matrix independently of clinical severity. So, a beneficial effect of antiresorptive treatments such as bisphosphonates (BP) is questionable. We aim to compare the bone matrix characteristics before and after BP pamidronate (PAM). Fifty-eight children (9 ± 5 yr-old) with OI (Type I, III, IV, V, VI, XI, or unknown) received intravenous PAM for 2 yr and underwent transiliac bone biopsies before (n = 57) and after (n = 35) treatment. Compared with age-matched controls, untreated OI was characterized by cortical and cancellous rarefaction. Two years of PAM in OI patients significantly decreased bone remodeling activity, increased cortical thickness, improved the maturation of both organic and mineral matrix, and most of the nanomechanical properties, despite further increase in the degree of mineralization. Overall, in addition to a gain in bone mass, our results showed for the first time that PAM is able to increase the maturation of mineral crystals and collagen matrix contributing to its antifracture efficacy in OI patients.


  • OPN, BSP, and Bone Quality—Structural, Biochemical, and Biomechanical Assessment in OPN−/−, BSP−/−, and DKO Mice

    by Luc Malaval, Hélène Follet, Delphine Farlay, Evelyne Gineyts, Sebastien Rizzo, Charlene Thomas, Mathieu Maalouf, Myriam Normand, Brigitte Burt-Pichat, Wafa Bouleftour, et al.

    Osteopontin (OPN) and Bone Sialoprotein (BSP), abundantly expressed by osteoblasts and osteoclasts, appear to have important, partly overlapping functions in bone. In gene-knockout (KO, -/-) models of either protein and their double (D)KO in the same CD1/129sv genetic background, we analyzed the morphology, matrix characteristics, and biomechanical properties of femur bone in 2 and 4 month old, male and female mice. OPN−/− mice display inconsistent, perhaps localized hypermineralization, while the BSP−/− are hypomineralized throughout ages and sexes, and the low mineralization of young DKO mice recovers with age. The higher contribution of primary bone remnants in OPN−/− shafts suggests a slow turnover, while their lower percentage in BSP−/− indicates rapid remodeling, despite FTIR-based evidence in this genotype of a high maturity of the mineralized matrix. In 3-point bending assays, OPN−/− bones consistently display higher Maximal Load, Work to Max. Load and in young mice Ultimate Stress, an intrinsic characteristic of the matrix. Young male and old female BSP−/− also display high Work to Max. Load along with low Ultimate Stress. Principal Component Analysis confirms the major role of morphological traits in mechanical competence, and evidences a grouping of the WT phenotype with the OPN−/− and of BSP−/− with DKO, driven by both structural and matrix parameters, suggesting that the presence or absence of BSP has the most profound effects on skeletal properties. Single or double gene KO of OPN and BSP thus have multiple distinct effects on skeletal phenotypes, confirming their importance in bone biology and their interplay in its regulation.


  • Open Access

    Dietary supplementation with nacre reduces cortical bone loss in aged female mice

    by Dung Kim Nguyen, Arnaud Vanden-Bossche, Norbert Laroche, Mireille Thomas, Marie-Thérèse Linossier, Sylvie Peyroche, Delphine Farlay, Hélène Follet, Patrice Laquerrière, Marie-Hélène Lafage-Proust, et al.


  • Open Access

    Material and nanomechanical properties of bone structural units of cortical and trabecular iliac bone tissues from untreated postmenopausal osteoporotic women

    by Delphine Farlay, Guillaume Falgayrac, Camille Ponçon, Sébastien Rizzo, Bernard Cortet, Roland Chapurlat, Guillaume Penel, Isabelle Badoud, Patrick Ammann, Georges Boivin


  • Intrinsic properties of osteomalacia bone evaluated by nanoindentation and FTIRM analysis

    by I. Hadjab, D. Farlay, P. Crozier, T. Douillard, G. Boivin, J. Chevalier, S. Meille, H. Follet


  • Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 years

    by Delphine Farlay, Sébastien Rizzo, David W Dempster, Shuang Huang, Arkadi Chines, Jacques P Brown, Georges Boivin

    In postmenopausal women with osteoporosis, denosumab (DMAb) therapy through 10 years resulted in significantly higher degree of mineralization of bone, with a subsequent increase from years 2–3 to year 5 and no further difference between years 5 and 10. Our aim was to assess the variables reflecting the quality of bone mineral and organic matrix (Fourier transform infrared microspectroscopy), and the microhardness of bone (Vickers microindentation). Cross-sectional assessments were performed in blinded fashion on iliac bone biopsies from osteoporotic women (72 from FREEDOM trial, 49 from FREEDOM Extension trial), separately in cortical and cancellous compartments. After 2–3 years of DMAb, mineral/matrix ratio and microhardness of cortical bone were significantly higher compared with placebo, whereas mineral maturity, mineral crystallinity, mineral carbonation, and collagen maturity were not different in both bone compartments. Through 5 years of DMAb, mineral carbonation was significantly lower and mineral/matrix ratio, mineral maturity, and crystallinity were significantly higher versus 2–3 years and were not different between 5 and 10 years, with the exception of mineral maturity in cancellous bone. These data support a transition of mineral to more mature crystals (within physiological range) and the completeness of secondary mineralization within 5 years of DMAb treatment. Microhardness in cortical and cancellous compartments was significantly lower at 5 years of DMAb versus 2–3 years and was not different from years 5 to 10. The lower microhardness at years 5 and 10 is likely the result of maturation of the organic matrix in a persistently low state of bone remodeling over 5 and 10 years. © 2022 American Society for Bone and Mineral Research (ASBMR).


  • Open Access

    Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture

    by Delphine Farlay, Sébastien Rizzo, Louis-Georges Ste-Marie, Laëtitia Michou, Suzanne N Morin, Shijing Qiu, Pascale Chavassieux, Roland D Chapurlat, Sudhaker D Rao, Jacques P Brown, et al.

    Bisphosphonates (BPs) are the most widely used drugs for the treatment of osteoporosis but prolonged use of BPs might increase the risk of atypical femur fracture (AFF). There are only a few studies that address the bone material quality in patients on long-term BP treatment with or without AFFs. We analyzed 52 trans-iliac bone biopsies from patients on long-term BP therapy with (n = 26) and without (n = 26) AFF. At the microscopic level, the degree of mineralization of bone (DMB) was assessed on whole bone by X-ray digitized microradiography while microhardness by Vickers microindentation, and bone matrix characteristics by Fourier transform infrared microspectroscopy (FTIRM) (mineral/organic ratio, mineral maturity and crystallinity, and collagen maturity) were measured at random focal areas. The AFF patients were treated longer than non-AFF patients (9.7 ± 3.3 years versus 7.9 ± 2.7 years). As expected, bone remodeling was low in both groups, without difference between them. The AFF group had significantly higher DMB in cortical bone (+2.9%, p = .001), which remained so after adjusting for treatment duration (p = .007), and showed a trend in cancellous bone (+1.6%, p = .05). Consistent with higher DMB, heterogeneity index (HI) was lower in the AFF than in the non-AFF group, illustrating lower heterogeneity of mineralization in the AFF group. A significant positive correlation between the duration of treatment and DMB in cortical bone was found in AFF, and not in the non-AFF group. Microhardness and bone matrix characteristics were similar between groups. We conclude that the AFF group had a duration-dependent increase in DMB leading to a significantly higher DMB than the non-AFF. Because BPs have high affinity to bone mineral and lining the walls of the osteocyte lacunae, the accumulation of matrix-bound BPs in AFF could lead to inhibition of the osteocyte cytoskeleton blunting their response to mechanical strains, a hypothesis to be further investigated. © 2021 American Society for Bone and Mineral Research (ASBMR).


  • Bone remodeling and bone matrix quality before and after menopause in healthy women

    by D. Farlay, Y. Bala, S. Rizzo, S. Bare, J.M. Lappe, R. Recker, G. Boivin


  • Anisotropic elastic properties of human femoral cortical bone and relationships with composition and microstructure in elderly

    by Xiran Cai, Hélène Follet, Laura Peralta, Marc Gardegaront, Delphine Farlay, Rémy Gauthier, Boliang Yu, Evelyne Gineyts, Cécile Olivier, Max Langer, et al.


  • Uranium Effect on Osteocytic Cells In Vitro

    by Lucile Hurault, Gaelle Creff, Agnès Hagège, Sabine Santucci-Darmanin, Sophie Pagnotta, Delphine Farlay, Christophe Den Auwer, Valérie Pierrefite-Carle, Georges F Carle

    Once absorbed in the body, natural uranium [U(VI)], a radionucleotide naturally present in the environment, is targeted to the skeleton which is the long-term storage organ. We and others have reported the U(VI) negative effects on osteoblasts (OB) and osteoclasts (OC), the main two cell types involved in bone remodeling. In the present work, we addressed the U(VI) effect on osteocytes (OST), the longest living bone cell type and the more numerous (> 90%). These cells, which are embedded in bone matrix and thus are the more prone to U(VI) long-term exposure, are now considered as the chief orchestrators of the bone remodeling process. Our results show that the cytotoxicity index of OST is close to 730 µM, which is about twice the one reported for OB and OC. However, despite this resistance potential, we observed that chronic U(VI) exposure as low as 5 µM led to a drastic decrease of the OST mineralization function. Gene expression analysis showed that this impairment could potentially be linked to an altered differentiation process of these cells. We also observed that U(VI) was able to trigger autophagy, a highly conserved survival mechanism. Extended X-ray absorption fine structure analysis at the U LIII edge of OST cells exposed to U(VI) unambiguously shows the formation of an uranyl phosphate phase in which the uranyl local structure is similar to the one present in Autunite. Thus, our results demonstrate for the first time that OST mineralization function can be affected by U(VI) exposure as low as 5 µM, suggesting that prolonged exposure could alter the central role of these cells in the bone environment.